I agree that this site is using cookies. You can find further informations here.
X
Björn Wahlin
143  results:
Search for persons X
?
1

S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVID..:

Sureda, Anna ; Falchi, Lorenzo ; Leppa, Sirpa...
HemaSphere.  7 (2023)  S3 - p. e5547136 , 2023
Link: https://doi.org/10.1097/..
 
?
2

Sting Is Commonly and Differentially Expressed in T- and Nk..:

Xagoraris, Ioanna ; Farrajota Neves da Silva, Pedro ; Kokaraki, Georgia...
Cancers.  14 (2022)  5 - p. 1186 , 2022
Link: https://doi.org/10.3390/..
 
?
3

Impact of COVID-19 on patients treated with autologous hema..:

Silfverberg, Thomas ; Wahlin, Björn ; Carlson, Kristina.
Upsala Journal of Medical Sciences.  127 (2022)  - p. , 2022
Link: https://doi.org/10.48101..
 
?
4

High‐dose therapy and autologous stem cell transplantation ..:

Avivi, Irit ; Arcaini, Luca ; Ferretti, Virginia V....
British Journal of Haematology.  182 (2018)  6 - p. 807-815 , 2018
Link: https://doi.org/10.1111/..
 
?
5

Immune Cell Modulations in Nordic FL Patients After Lenalid..:

Lockmer, Sandra ; Jeppsson-Ahlberg, Åsa ; Sander, Birgitta..
Clinical Lymphoma Myeloma and Leukemia.  16 (2016)  - p. S111-S112 , 2016
Link: https://doi.org/10.1016/..
 
?
6

Biomarker analysis of the ASPEN study comparing zanubrutini..:

Tam, Constantine S. ; Opat, Stephen ; D'Sa, Shirley...
Blood Advances.  8 (2024)  7 - p. 1639-1650 , 2024
Link: https://doi.org/10.1182/..
 
?
7

High Complete Metabolic Response Rates with Epcoritamab SC ..:

Brody, Joshua ; Jørgensen, Judit ; Belada, David...
Transplantation and Cellular Therapy.  30 (2024)  2 - p. S357 , 2024
Link: https://doi.org/10.1016/..
 
?
8

The National Swedish Lymphoma Register – a systematic valid..:

Ekström Smedby, Karin ; Eloranta, Sandra ; Wästerlid, Tove...
Acta Oncologica.  63 (2024)  - p. 563-572 , 2024
Link: https://doi.org/10.2340/..
 
?
9

Redirecting NK cells to the lymph nodes to augment their ly..:

Sanz-Ortega, Laura ; Leijonhufvud, Caroline ; Schoutens, Lisanne...
npj Precision Oncology.  8 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
10

Treatment sequencing and impact of number of treatment line..:

Wästerlid, Tove ; Dietrich, Caroline E. ; Oksanen, Anna...
eJHaem.  5 (2024)  3 - p. 516-526 , 2024
Link: https://doi.org/10.1002/..
 
?
11

POSTER: IBCL-474 Epcoritamab + R2 Regimen and Responses in ..:

Merryman, Reid W. ; Belada, David ; Sureda, Anna...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S210 , 2023
Link: https://doi.org/10.1016/..
 
?
12

Genetic and transcriptomic analyses of diffuse large B-cell..:

Ren, Weicheng ; Wan, Hui ; Own, Sulaf Abd...
Leukemia.  38 (2023)  3 - p. 610-620 , 2023
Link: https://doi.org/10.1038/..
 
?
13

ADAR1-mediated RNA editing promotes B cell lymphomagenesis:

Pecori, Riccardo ; Ren, Weicheng ; Pirmoradian, Mohammad...
iScience.  26 (2023)  6 - p. 106864 , 2023
Link: https://doi.org/10.1016/..
 
?
14

Splenic marginal zone lymphoma in Sweden 2000–2020: Increas..:

Junlén, Henna‐Riikka ; Sonnevi, Kristina ; Lindén, Ola...
eJHaem.  4 (2023)  3 - p. 647-655 , 2023
Link: https://doi.org/10.1002/..
 
?
15

Survival by First-line Treatment Type and Timing of Progres..:

Weibull, Caroline E. ; Wästerlid, Tove ; Wahlin, Björn Engelbrekt...
HemaSphere.  7 (2023)  3 - p. e838 , 2023
Link: https://doi.org/10.1097/..
 
1-15